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Introduction
The second half of a normal pregnancy results in metabolic stress and is characterized by progressive insulin resistance, hyperinsulinemia, and by mild postprandial hyperglycemia (1) . Gestational diabetes mellitus (GDM), glucose intolerance that arises during pregnancy, develops in 4-7% of pregnancies and is associated with fetal and maternal morbidities (2) . The metabolic abnormalities of GDM are similar to those of type 2 diabetes (T2DM) (1) , as are the known risk factors.
Hormonal contraceptives (HCs) are used by at least 10 million women in the US (3) . The synthetic progestins used in HCs are structurally related to testosterone and may also produce androgenic side effects. The metabolic effects of androgens include reduced glucose tolerance (4) and weight gain (5) . Women who have taken HCs might be more vulnerable to the metabolic stress induced by placental hormones in late pregnancy (6) , and might be more likely to develop GDM.
HCs all contain a progestin component and are available in a variety of forms: combination oral contraceptive (OC) pills (containing both progestin and estrogen), progestin-only oral contraceptive pills, injectable progestins and progestin implants. Currently available HCs differ from one another in dose and the degree of androgenicity of the progestin. Early metabolic studies of combined OCs suggest that formulations with higher doses of the more androgenic forms of progestins (such as norgestrel and levonorgestrel) are associated with greater alterations of glucose metabolism (7) (8) (9) (10) . New formulations of OCs, with lower doses of progestins, have been formulated to decrease these side effects. The results of studies of low dose formulations and glucose metabolism among women with normal glucose tolerance have been conflicting. Two studies found no changes in glucose tolerance (11, 12) , whereas one studies found that certain low dose progestin formulations had slightly reduced glucose tolerance (13) . It is unclear whether the small effects observed on glucose tolerance with the use of certain HCs are large enough to be clinically relevant.
Data are limited on HC use during the years immediately before pregnancy and GDM risk. The present study examines the association between HC use in the five years before pregnancy and GDM risk in a nested case-control study, using data from the Kaiser Permanente Medical Care Program of Northern California (KP, thereafter). Using medical records and some pharmacy data, we sought to assess GDM risk in relation to the androgenicity of the progestins used.
Research Design and Methods
The setting of the study was the KP, which provides comprehensive medical services to over 3 million members located in a 14-county region in Northern California. The KP membership represents approximately 30% of the population and is demographically, ethnically and socioeconomically representative of the area, except that membership under represents the very poor and the very wealthy (14) . From January 1, 1996 to June 30, 1998, approximately 94% of all pregnancies that reached the third trimester were screened for GDM by a 50-gram, 1-hour oral glucose challenge test (GCT). If abnormal [1-hour plasma glucose levels >= 140 mg/dl], this test was followed by a diagnostic 100-g, 3-hour oral glucose tolerance test (OGTT) performed in the morning after a 12 hour fast (15).
We searched the KP hospital discharge and billing claims databases to identify all singleton live births and searched the KP laboratory database to obtain all plasma glucose values measured during screening GCTs and diagnostic 3-hour OGTT(16). We restricted our cohort to women who delivered between January 1996 and June 1998 without previously recognized diabetes (n= 72,946).
We excluded pregnancies not screened for GDM by a 50-g, 1-h OCT in the laboratory database (n=4,560), pregnancies screened for GDM outside of the recommended 24-28 weeks' gestation (n=21,297) and women with a diagnosis of GDM in a prior pregnancy (n=362). Finally, we excluded women who were not continuous health plan members for 5 years prior to the index pregnancy (n=32,492), leaving 14,235 eligible pregnancies from which to select cases and controls. Compared to the entire cohort of 72,946 women who delivered during the study period, the 14,235 women who were eligible to be selected as cases and controls for the current study were more likely to be over the age 35 at pregnancy (23.6% versus 15.7%) and to be non-hispanic White (57.1% versus 47.0%), but there were no differences in parity and education. Trained medical records abstractors completed chart reviews and confirmed that the inclusion criteria were met and none of the exclusion criteria were present.
Women were classified as having GDM if two or more of the four plasma glucose values obtained during the 100-g, 3-h OGTT were abnormal according to the NDDG criteria(2): fasting >105 mg/dl; 1-h >190 mg/dl; 2-h >165 mg/dl; 3-h >145 mg/dl. If a woman had more than one diagnostic test performed, we used the latest test performed in pregnancy.
We performed medical chart review of all of the 437 potential GDM cases we identified electronically. Medical chart review revealed 26 (5.9%) were ineligible due to having their screening test performed outside of the 24-28 weeks' gestation window, 12 (2.7%) were ineligible because they had GDM in a prior pregnancy noted in their chart and 10 (2.3%) had insufficient information in their medical charts to determine eligibility, leaving 391 eligible cases.
Eligible controls were women without GDM, by the National Diabetes Data Group (NDDG) criteria, whose records confirmed the absence of exclusion criteria. Three hundred ten controls were previously randomly selected and had their medical records abstracted for a casecontrol study of maternal hyperglycemia and infant complications (hypoglycemia, hyperbilirubinemia and macrosomia) among women without GDM(17). Due to the selection criteria of that study, only 1.8% had at least one of the infant complications of interest, in contrast to 8.3% of potential controls. Therefore, to ensure that the controls for this study were representative of the entire cohort, we randomly selected an additional 28 controls from among pregnant women whose infants had at least one of the four complications and an additional 30 women whose infants did not have any of the complications. Thus, there were a total of 368 controls and 8.9% of them had an infant with one or more of the complications listed above. In order to ensure that the control group we selected was representative of the 13,798 potential controls, we compared our controls with the entire sample of potential controls and found no significant differences in age, race and infant complications.
Medical chart abstracters recorded all information on HC use found in the medical charts or electronic databases during the five years before the women's index pregnancies. First, they recorded the date, type and duration of each prescription found in the chart. Second, they searched KP's computerized pharmacy, laboratory, and outpatient databaseswhich records all drugs prescribed by KP physicians and dispensed in KP outpatient pharmacies. For each prescription, the database includes the date it was filled, the dosage and formulation. Abstractors recorded the date and type of any prescriptions. Finally, any additional information found in the medical charts pertaining to HC use was recorded, such as the type of HC, months of use, discontinuation, and the LMP dates of any pregnancies occurring in the five year window. They also abstracted information on other medical conditions that are indications or contraindications for various HC regimens and associated with glucose tolerance, including: amenorrhea, polycystic ovarian syndrome, infertility, fibroids, depression, hypothyroid, smoking status, hypertension and elevated cholesterol (> 200 mg/dl) as well as information on date of last menstrual period (LMP) for the index pregnancy, marital status, parity and height were abstracted from the form completed at the first prenatal visit Pre-pregnancy weight was defined as the last recorded weight found in the chart prior to the woman's LMP for the index pregnancy. For the 14.4% of women for whom these data were not available, the self-reported weight on the prenatal form was used. Prepregnancy body mass index (BMI) was calculated as prepregnancy weight (kg) divided by height squared (m 2 ). Women's self reported race-ethnicity and education were obtained by linkage to the electronic birth certificate database.
The androgenicity of the progestin component in each OC was determined by compiling data from previous studies assessing the androgenic potential of progestins, while also factoring in the dose of progestin per OC formulation(18)..
The overall androgenic activity of a progestin also depends on the pharmokinetics of the progestin and the dose. A higher-potency progestin may be used in a much smaller dose and be equivalent to a larger dose of a less-potent progestin in terms of androgenicity. Table 1 shows the androgenicity of the OCs most commonly used by study participants.
We used Dickey's classification of androgenic activity (19). The androgenic activity was determined by the rat ventral prostate assay, with methyl testosterone used as the standard(19,20). We classified any OC with an androgenic activity of 0.47 mg of methyl testosterone equivalents per 28 days(19) or higher as "high androgen". There is no clearly defined cut-off for what constitutes a "high androgen" HC since most HCs contain some degree of androgenicity. This cut-off encompased OCs in the highest quartile of androgenicity among OCs used by the study population.
For HCs that are not orally administered, we classified Norplant as "high androgen" since it contains levonorgestrel, a progestin with high androgenic activity. For depomedroxyprogesterone acetate (DMPA), which contains medroxyprogesterone, a progestin with low androgenic activity, we assigned the classification "low-androgen".
Using the information obtained from medical charts, pharmacy databases and information found in the medical chart we calculated the duration of use and time since discontinuation of HCs. We categorized women as having taken a high androgen HC if they took any highandrogen HC for at least 6 months (regardless of whether they also took a low-androgen HC).. Low-androgen HC users were women who took only lowandrogen HCs for at least 6 months, and non-users were women who did not take either type. Because women who discontinue pill use shortly after starting may be different from those continue use, women who used either type of HC for less than 6 months were excluded. Analytic Dataset Of the eligible 391 cases and 368 controls, we excluded women who used an HC for less than 6 months (29 cases and 25 controls). Women who could not be classified into categories of high or low androgen HC use because of missing information on HC formulations or duration (n=3 cases and n=7 controls) were also omitted from our analyses.
Statistical analyses were performed using unconditional logistic regression. Odds ratios were computed as estimates of the relative risk of GDM as a function of each category of HC use. Potentially confounding factors were entered individually as covariates in the models, those that changed the odds ratio estimates of the relationship between HC use and GDM by more than 10% were included in the covariate adjusted models. These factors included age (continuous), raceethnicity (non-white Hispanic, Asian, Hispanic, African American, Other, Unknown) and a history of infertility (yes/no). We ran a third model further adjusting for pre-pregnancy BMI. Trends across levels of exposure to HCs (e.g. duration of use) were assessed examining p-values for a single trend variable coded as the category of exposure (1,2,3, etc. ). This study was approved by the human subjects committee of the Kaiser Foundation Research Institute. Table 2 compares cases and controls with regard to demographic factors, reproductive factors and selected medical conditions. Relative to controls, cases were more likely to be older than 30, to be from a race-ethnic minority group and to be married, but were similar with respect to education. Cases were also more likely to have 2 or more prior live births, to have a high pre-pregnancy BMI, to have a first degree family history of diabetes and to have certain other medical conditions: infertility, amenorrhea, fibroids and elevated serum cholesterol. After adjusting for covariates, there was some suggestion of a greater decreased risk of GDM with longer duration of use of a low-androgen, but no clear trend was evident with duration of use of a highandrogen HC (Table 3 ). The reduced risk of GDM associated with use of a lowandrogen HC was greatest when use was discontinued less than 6 months prior to pregnancy (Table 4 ). In contrast, the increased risk of GDM associated with use of a high androgen HC was greatest when use was discontinued more than one year before pregnancy (Table 4) .
Results

Discussion
In this study, women with GDM were slightly less likely than controls to have used a low-androgen HC in the five years before pregnancy, and more likely to have used a high-androgen contraceptive. There was a suggestion of a trend of greater decrease in risk with longer duration of use of a low androgen HC, but no clear pattern of GDM risk was observed with highandrogen HC use. However, the statistical precision of our results was not great, and given no true associations chance alone plausibly could have been responsible for those we did observe.
A strength of this study is the use of medical records and the computerized pharmacy database to ascertain contraceptive use. Since the data were recorded in medical records, use of this information eliminates the potential for recall bias. Contraceptives are a covered benefit by the health plan; thus, there is incentive for KP members to have prescriptions made by a KP physician and to use the KP pharmacy. . Therefore, the possibility of missing HC prescriptions is minimized. It is also possible that some women who had prescriptions noted in the medical chart or electronic database did not actually take the pills. Misclassification from these sources would likely be similar for cases and controls, biasing risk estimates toward the null.
A limitation of the study is that we were also limited to data on HC use during the 5 years before pregnancy. There is some evidence that hyperglycemia associated with HCs abates when exposure ceases.(8) However, the "glucose toxicity" theory suggests that any prolonged exposure to hyperglycemia can cause detrimental effects to pancreatic β-cell function, leading to the progressive worsening of hyperglycemia(23).
If this theory is correct, we may have misclassified some women who stopped using HCs more 5 years ago as non-users. The misclassification would likely be non-differential and, therefore, would have biased our results toward the null.
To our knowledge, this is the first study to examine use of HCs and subsequent risk of GDM. Previous information on HC use and carbohydrate intolerance comes largely from metabolic studies, which examined changes in glucose and insulin levels in normal women after taking OCs. Clinical studies conducted on the early high dose OC formulations consistently found that use of these formulations increased serum glucose and insulin levels (24-27). Later studies found that the degree of metabolic alteration varied by type and dose of the progestin component, (10, 28) and that the more androgenic formulations consistently had the strongest effects(7-9,29).
Other data support an association between hyperandrogenicity and insulin resistance. Polycystic ovary syndrome (PCOS), is a reproductive condition characterized by increased serum levels of circulating adrenal androgens, anovulation and insulin resistance(30). The risk of GDM appears to be higher among women with PCOS compared to women without PCOS. (30, 31 Our results suggest that the effects of HC use on risk of GDM may vary by the androgenicity of the progestin component. We found evidence suggesting a 16% reduced risk of GDM associated with use of low-androgen HCs and a 43% increased risk associated with use of high-androgen HCs. However, these observations should be interpreted cautiously pending the results of other studies addressing this question. 
